Ju Fu Tang Biotech Holdings Co., Ltd Overview
Ju Fu Tang Biotech is a Hong Kong micro-cap in transition. Its revenue base is still almost entirely a small civil engineering and fit-out subcontracting business, now overlaid with an investment portfolio and an embryonic medical-device trading arm. In FY2026, 94% of revenue (HK$35.4M) came from roads and drainage, structural works, site formation and decoration subcontracting for a highly concentrated client base. One customer contributed 85% of revenue. A new "health technology" segment sold HK$2.1M of medical devices through a newly formed Shenzhen subsidiary. The return to a reported profit of HK$23.3M was driven by HK$27.4M of fair-value gains on Hong Kong-listed equities, not by operations. Operating margins in construction remain near break-even. The 2025 rebranding to a "biotech" name signals management's intent to pivot towards wellness, elderly-care and medical technology serving the Greater Bay Area. That strategy is, however, at an early stage and is not yet resourced at scale.
Company's own description (paraphrased from the FY2026 Annual Report)
The Group describes itself as engaged in three activities: (1) civil engineering and construction; (2) health technology and medical-product sales; and (3) investment holding. The Company itself is an investment holding company.
The ESG report states that, despite the English name change during the year, the Group's principal business remains that of a civil engineering subcontractor in Hong Kong. Its civil works fall into four categories:
Roads and drainage: building and improving local roads, carriageways with junction improvements and associated footpaths, planting areas, drains, sewers, water mains and utility diversions.
Structural works: reinforced concrete structures, including bridges and retaining walls.
Site formation: excavation and/or filling to form new sites or reach designed formation levels.
Decoration and renovation: fit-out works including carpentry, marble, plastering, ceiling installation and project-management support.
The health technology business sells medical-device products. Revenue is recognised at the point the customer accepts delivery. Management concluded that the Group acts as principal in these sales because it controls inventory before transfer and bears inventory risk.
Business model and revenue model
| Dimension | Characterisation | Evidence |
|---|---|---|
| Revenue model mix | Project or contract services (94.4% of FY2026 revenue) plus product sales (5.6%). There is no subscription or licensing revenue. | FY2026 AR note 8 |
| Pricing | Construction work is priced cost-plus at tender. Mark-ups are lower on larger contracts and adjusted for complexity, uncertainty and competition. Contracts have fixed prices with milestone payments. | FY2026 AR MD&A, note 8 |
| Retention | Clients typically withhold 5–10% of contract value as retention for 1–2 years. This sits in contract assets until the defects period ends. | FY2026 AR note 20 |
| Recognition | Construction revenue is recognised over time using an output method based on surveys and interim payment applications. Medical-device revenue is recognised at a point in time. | FY2026 AR note 3 |
| Value-chain position | Tier-2/3 subcontractor beneath main contractors. Construction waste is handled by the main contractor. Heavy reliance on sub-subcontractors: the largest subcontractor took 58% of subcontracting spend and the top five took 99%. | FY2026 AR ESG and Directors' Report |
| Customer types | Main contractors on public and private civil works in Hong Kong. The top five customers have mostly worked with the Group for more than 10 years. Medical-device customers are in the PRC (names not disclosed). | FY2026 AR |
| End-markets | Hong Kong public infrastructure and private development (civil); PRC medical-device distribution (health technology); Hong Kong-listed equities (investment). | FY2026 AR |
Independent characterisation
In economic terms, the Group is three things:
-
A sub-scale, low-margin construction subcontractor. Gross margin was 2.7% in both FY2025 and FY2026.
-
A concentrated small-cap equity portfolio. HK$51.4M at 31 March 2026, equal to 55.5% of total assets and more than the Group's entire equity. Its mark-to-market swings now drive reported earnings.
-
An optional pivot into health and wellness. The "Ju Fu Tang" (菊福堂) brand and the health-care (康養) business led by general manager Mr. Cai Chunzhi (蔡淳治) were cited as reasons for the 2025 name change. So far this has produced HK$2.1M of medical-device revenue and a segment loss of HK$19k.
The investment case is therefore driven by net asset value and catalysts rather than by earnings power.
Strategy
Stated strategy (paraphrased themes from the FY2026 Chairman's Statement)
-
Dual-engine strategy. Build a more resilient, diversified group by combining a stabilised construction division with a growing health technology and medical-device sales business.
-
Construction: target resilient public-sector demand. Management cites the HK Government's 2026–27 Budget, which projects average annual capital works spending of about HK$120bn over the five years to 2030–31 and recurrent spending growth of about 3.6% per year. It intends to widen participation in public-sector work and pursue workforce certifications to win higher-value contracts.
-
Health technology: ride policy-led precision medicine. Management cites the "Healthy China 2030" and 15th Five-Year Plan frameworks and an estimated US$17–19bn domestic AI-healthcare market by 2030. It plans to:
-
embed AI solutions in clinical workflows;
-
use Hong Kong's forthcoming medicines regulator, the "1+" approval mechanism and the Drug and Device Connect scheme to speed up cross-border registrations;
-
use the Hetao (Loop) cooperation zone and Greater Bay Area partnerships to move medical technologies from research to clinical use.
-
-
Opportunistic diversification. Management says it will continue to seek new business opportunities to diversify revenue and improve market position.
-
Investment portfolio. Maintain a diversified, flexible portfolio aimed at long-term returns while keeping the core business stable.
Initiatives announced in the last 24 months
| Date | Initiative | Detail / status |
|---|---|---|
| 10 Jun 2025 | Rebrand to Ju Fu Tang Biotech | Rationale: new corporate identity to support the health-care (康養) business under GM Mr. Cai Chunzhi and broaden revenue. Completed 11 Sep 2025. |
| 8 Sep 2025 | 2025 Share Option Scheme | 10-year scheme. Mandate of 30,186,000 shares (10%). No options granted under it to date. |
| FY2026 | Incorporation of Anjulai Biotechnology (Shenzhen) | Registered capital US$200k, unpaid at year end. Generated HK$2.11M of revenue. |
| FY2026 | Incorporation of Right Estate Limited (BVI) | Investment holding vehicle. |
| FY2026 | Disposal of owned office | HK$2.92M proceeds and HK$2.80M gain. Reduces fixed assets to nil. |
| FY2026 | Cost programme | Staff costs cut 40% (HK$5.06M to HK$3.03M); admin costs down 8.8%. No formal target disclosed. |
| FY2026 | Climate disclosure | Adopted HKEX climate framework (IFRS S2-based). Target to maintain or reduce Scope 1+2 and energy intensity over the next three fiscal years from the FY2026 baseline. |
Medium-term targets and guidance
The company provides no revenue, margin or return targets, and no quantitative guidance. The only quantitative forward-looking disclosures are the ESG intensity targets and the HK$32.8M of remaining performance obligations expected to be recognised within one year.
Products & Services
The Group does not disclose brand names, SKUs, product specifications or price lists for any offering. The catalogue below is built from filing descriptions.
Civil engineering, decoration & renovation segment
| Offering | Description / capabilities | Target customer | Launch / status | Pricing model |
|---|---|---|---|---|
| Roads and drainage works | Construction and improvement of local roads, carriageways and junctions, footpaths, planting areas, drains, sewers, water mains, utility diversion | Main contractors on public works (e.g. government projects) and private developments | Core legacy service (25+ years) | Fixed-price contracts tendered cost-plus, milestone billing, 5–10% retention |
| Structural works | Reinforced concrete structures including bridges and retaining walls | Main contractors | Core legacy service | Same |
| Site formation works | Excavation and/or filling to form new sites or achieve design levels | Main contractors and developers | Core legacy service | Same |
| Decoration and renovation works | Interior fit-out: carpentry, marble, plastering, ceiling installation, project-management support | Main contractors and building owners | Expanded in recent years via 穆倫建業 | Same |
| Maintenance services | Maintenance related to completed works | Existing clients | Ongoing | — |
Order book: 13 contracts on hand with total contract value of HK$394.23M at 31 Mar 2026 (12 contracts, HK$346.89M, at 31 Mar 2025). Transaction price allocated to unsatisfied obligations and expected to be recognised within one year was HK$32.8M (HK$31.3M prior year) (FY2026 AR MD&A and note 8). The gap between total contract value and remaining performance obligations suggests most listed contracts are substantially complete.
Health technology segment
| Offering | Description | Target customer | Launch | Pricing |
|---|---|---|---|---|
| Medical-device product sales | Wholesale and trading of medical-device products via Anjulai Biotechnology (Shenzhen). Specific devices are not publicly disclosed. Warranty is assurance-type, with returns limited to quality defects. | PRC customers (not named) | FY2026 | Per-order sale; principal accounting |
| Health care / wellness (康養) business | Cited in the June 2025 name-change rationale as led by GM Mr. Cai Chunzhi. No separate revenue disclosed. | — | In development | — |
| AI-enabled clinical solutions and cross-border registration (stated ambition) | The Chairman's Statement describes intentions to embed AI solutions into clinical workflows, use Hong Kong's new regulatory channels (planned HK medicines regulator, "1+" approval mechanism, Drug and Device Connect) for faster cross-border registration, and build Greater Bay Area partnerships. | — | Aspirational; no product launched | — |
Investment holding activities
| Holding (HK-listed) | Shares held | Stake | Cost (HKD K) | Fair value 1 Apr 2025 (HKD K) | Fair value 31 Mar 2026 (HKD K) | FY2026 gain/(loss) (HKD K) | % of total assets |
|---|---|---|---|---|---|---|---|
| 滙隆控股有限公司 (GEM; scaffolding and fitting-out) | 381,660,000 | 2.66% | 9,762 | 14,885 | 3,817 | (11,068) | 4.1% |
| 亞洲策略數字科技控股有限公司 (Main Board; umbrella manufacturing) | 9,100,000 | 2.21% | 1,820 | 8,281 | 27,846 | 19,565 | 30.1% |
| Tam Kam Holdings Limited (GEM) | 7,212,000 | 1.34% | 8,535 | 1,875 | 10,241 | 8,366 | 11.1% |
| Nine other HK-listed equities (each below 5% of total assets) | — | — | — | 3,018 | 9,473 | — | 10.2% |
| Total | — | — | — | 28,059 | 51,377 | — | 55.5% |
Source: FY2026 AR MD&A.
The investment policy permits shares, bonds, funds, insurance products and deposits. It prohibits excessive leverage, unlisted securities and speculative derivatives. The two executive directors can approve single investments below 5% of market capitalisation or total assets; larger investments require board approval.
Financial Narrative
Sources and conventions. FY2026 and FY2025 figures are from the FY2026 audited financial statements. Revenue, profit before tax, net result, total assets, total liabilities and net assets for FY2022–FY2024 are from the FY2026 AR five-year summary.
Income statement
FY2022 EPS uses the weighted average of 200.74M shares (rights issue year). FY2023–FY2024 EPS is computed on 301.86M shares. FY2025–FY2026 EPS is as reported.
Margins
Revenue CAGR: FY2022–FY2026 (4 years) is approximately -20.2% per year. From the FY2017 peak (HK$735M, aggregator) to FY2026, revenue has fallen roughly 95%.
Commentary on the income statement. Reported earnings are almost entirely non-operating. Of the HK$24.0M operating profit in FY2026, HK$27.4M came from unrealised and realised fair-value gains on listed equities and HK$2.8M from selling the office property. A net HK$1.3M came from expected credit loss reversals: HK$7.2M of contract-asset recoveries, offset by a HK$6.0M trade-receivable impairment, of which HK$21.0M (gross) relates to a customer more than two years overdue.
Underlying construction economics remain marginal. Gross profit of HK$1.0M against administrative costs of HK$8.5M implies a core operating loss of about HK$7.5M before investment gains.
Administrative costs fell 8.8%, helped by lower staff costs (HK$3.0M versus HK$5.1M), lower marketing and lower severance. Professional fees rose to HK$1.25M (HK$0.50M prior year) and marketing expenses to HK$1.45M (HK$0.83M), consistent with the rebranding.
Other income fell from HK$1.39M to HK$12k because FY2025 included a HK$520k work-injury insurance recovery, HK$194k of government subsidy and a HK$648k long-service-payment over-provision reversal.
The inflection in FY2024 is notable. Revenue collapsed 66% as major projects completed. Management notes that revenue from its main customer fell about 36% between FY2023 and FY2026, in line with the broader Hong Kong construction market.
Balance sheet
FY2022 and FY2023 bond balances assume the HK$12M bond (drawn December 2020) remained outstanding. FY2024 cash is the opening cash balance for FY2025 per the cash flow statement.
FY2026 versus FY2025 detail (HK$k, FY2026 AR):
At company level, distributable reserves were nil at 31 March 2026, and the Company had an accumulated loss of HK$103.3M (note 31).
Cash flow
FY2026 operating cash flow was helped by HK$12.5M of contract-asset unwinding and HK$8.2M of receivable collections. Investing inflows comprise HK$5.76M of securities disposals, less HK$1.68M of purchases, plus HK$2.92M of property proceeds. Financing outflows were a HK$5.38M repayment to a subsidiary director and HK$2.26M to a former shareholder.
Ratios
Notes on the ratios:
-
ROE and ROA use average balances, except FY2022, which uses closing balances.
-
ROIC is operating profit divided by (equity plus bonds), with no tax because of tax losses.
-
Debt to equity counts only the HK$12M bond. The FY2025 and FY2026 figures match the reported gearing of 44% and 24%.
-
There is no inventory, so the cash conversion cycle equals DSO minus DPO.
-
Net debt to EBITDA is not meaningful for loss-making years.
Trend commentary. The balance sheet improved sharply in FY2026. Equity rose 86% to HK$50.5M and net debt fell to HK$2.7M. However, the quality of that improvement is weak.
First, 55% of assets are listed small-cap equities, two of which have extreme price histories. The 滙隆 stake lost 74% of its value in the year, while the 亞洲策略 stake rose more than threefold.
Second, the HK$12M 6% bond has been overdue since 2 December 2022 and accrued interest payable has reached HK$3.7M. The filings classify it as current and do not describe it as a default event. However, it represents a creditor claim of roughly HK$15.7M including interest, against only HK$9.3M of cash.
Third, credit quality in the receivable book is poor. The average expected loss rate on trade receivables is 64% (HK$21.1M of allowance on HK$33.0M gross).
Unrecognised tax losses of HK$81.0M (HK$98.8M prior year) provide a tax shield for future profits.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment revenue (HKD K)
| Segment revenue (HKD K) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Civil engineering, decoration & renovation | 35,141 | 36,202 | 35,441 |
Health technology (medical devices) | 0 | 0 | 2,114 |
Total revenue | 35,141 | 36,202 | 37,555 |
Segment Revenue
| Metric (FY2026) | Civil engineering, decoration & renovation | Health technology | Total / unallocated |
|---|---|---|---|
Segment revenue (HKD K) | 35,441 | 2,114 | 37,555 |
Cost of sales (HKD K) | (34,466) | (2,072) | (36,538) |
Segment gross margin | 2.75% | 1.99% | 2.71% |
Trade receivable impairment (HKD K) | (5,902) | (55) | (5,957) |
Contract asset impairment reversal (HKD K) | 7,201 | — | 7,201 |
Segment profit/(loss) (HKD K) | 437 | (19) | 418 |
Segment profit margin | 1.2% | (0.9%) | 1.1% |
YoY revenue growth | (2.1%) | n/m (new) | +3.7% |
Share of revenue | 94.4% | 5.6% | 100% |
Segment assets (HKD K) | 32,342 | 2,407 | 57,861 unallocated (mainly FVTPL) |
Segment liabilities (HKD K) | 21,919 | 2,427 | 17,729 unallocated |
Segment margin (%)
| Segment margin (%) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Civil engineering gross margin (%) | 5.35 | 2.71 | 2.75 |
Health technology gross margin (%) | — | — | 1.99 |
Group Entities
| Subsidiary | Place of incorporation / operation | Issued capital | Group interest | Principal activity |
|---|---|---|---|---|
Right Estate Limited | BVI | 5 shares of US$1 | 100% (direct; incorporated FY2026) | Investment holding |
| — | Hong Kong | 9,280,000 ordinary shares | 100% | Civil engineering works |
| — | Hong Kong | 10,000 ordinary shares | 100% (direct) | Decoration and renovation works |
Anjulai Biotechnology (Shenzhen) Company Limited (English name for identification only) | PRC | Registered US$200,000; paid-up nil | 100% (incorporated FY2026) | Wholesale and sale of medical-device products |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (HKD K) | 92,754 | 104,601 | 35,141 | 36,202 | 37,555 |
Revenue growth YoY (%) | -44.9 | 12.8 | -66.4 | 3.0 | 3.7 |
Gross profit (HKD K) | 1,040 | -2,880 | 1,880 | 982 | 1,017 |
Operating income (HKD K) | -19,480 | -9,240 | -16,710 | -5,179 | 24,038 |
EBITDA (HKD K) | -19,140 | -9,130 | -16,630 | -5,099 | 24,078 |
Finance costs (HKD K) | 733 | 721 | 720 | 720 | 720 |
Pre-tax income (HKD K) | -20,208 | -9,963 | -17,433 | -5,899 | 23,318 |
Net income attributable (HKD K) | -20,147 | -9,963 | -17,433 | -5,899 | 23,318 |
EPS basic (HK cents) | -10.04 | -3.30 | -5.78 | -1.95 | 7.72 |
EPS diluted (HK cents) | -10.04 | -3.30 | -5.78 | -1.95 | 7.62 |
Dividend per share (HK cents) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 1.12 | -2.75 | 5.35 | 2.71 | 2.71 |
Operating margin (%) | -21.00 | -8.83 | -47.55 | -14.31 | 64.01 |
EBITDA margin (%) | -20.64 | -8.73 | -47.32 | -14.08 | 64.11 |
Net margin (%) | -21.72 | -9.52 | -49.61 | -16.29 | 62.09 |
Financial Analysis
| Item | FY2025 | FY2026 |
|---|---|---|
Revenue | 36,202 | 37,555 |
Cost of services | (35,220) | (36,538) |
Gross profit | 982 | 1,017 |
Other income | 1,392 | 12 |
Other net gains (FVTPL change; property disposal) | 5,349 | 30,190 (27,391 FVTPL + 2,799 disposal) |
Expected credit loss (charge)/reversal, net | (3,549) | 1,345 |
Administrative and other operating expenses | (9,353) | (8,526) |
Operating profit/(loss) | (5,179) | 24,038 |
Finance costs | (720) | (720) |
Profit/(loss) before tax | (5,899) | 23,318 |
Profit/(loss) for the year | (5,899) | 23,318 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (HKD K) | 144,347 | 105,514 | 81,554 | 80,365 | 92,610 |
Total liabilities (HKD K) | 83,834 | 54,964 | 48,437 | 53,147 | 42,075 |
Total equity (HKD K) | 60,513 | 50,550 | 33,117 | 27,218 | 50,535 |
Cash and bank balances (HKD K) | — | — | 4,005 | 2,113 | 9,276 |
FVTPL listed equities (HKD K) | — | — | — | 28,059 | 51,377 |
Short-term debt — bonds payable (HKD K) | 12,000 | 12,000 | 12,000 | 12,000 | 12,000 |
Long-term debt (HKD K) | — | — | — | 0 | 0 |
Net debt (HKD K) | — | — | 7,995 | 9,887 | 2,724 |
Goodwill and intangibles (HKD K) | — | — | — | 0 | 0 |
Working capital — net current assets (HKD K) | — | — | — | 27,055 | 50,535 |
Margin Analysis (%) (31 Mar 2025–31 Mar 2026)
| Line item | 31 Mar 2025 | 31 Mar 2026 |
|---|---|---|
Property, plant and equipment | 163 | — |
Contract assets (net of ECL 2,201 / 9,402) | 13,558 | 8,250 |
Contract costs | 2,221 | 978 |
Trade and other receivables | 34,251 | 20,520 |
— of which trade receivables, net (gross 32,978; ECL 21,099) | 26,065 | 11,879 |
— of which receivable from securities broker | 907 | 4,475 |
— of which performance bond deposits | 7,215 | 4,107 |
Amount due from a related party (net) | — | 2,209 |
FVTPL financial assets | 28,059 | 51,377 |
Cash and bank balances | 2,113 | 9,276 |
Current assets | 80,202 | 92,610 |
Contract liabilities | 1,517 | 274 |
Trade and other payables (incl. retention payable 13,778; interest payable 3,737) | 36,739 | 29,174 |
Amount due to a former shareholder | 2,264 | — |
Bonds payable (6%, matured 2 Dec 2022) | 12,000 | 12,000 |
Tax payable | 627 | 627 |
Current liabilities | 53,147 | 42,075 |
Net assets | 27,218 | 50,535 |
Share capital | 48,298 | 48,298 |
Reserves | (21,080) | 2,237 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (HKD K) | — | — | — | -7,270 | 7,810 |
Capex (HKD K) | — | — | — | 0 | 0 |
Free cash flow (HKD K) | — | — | — | -7,270 | 7,810 |
Investing cash flow (HKD K) | — | — | — | 0 | 6,995 |
Financing cash flow (HKD K) | — | — | — | 5,378 | -7,642 |
Dividends paid (HKD K) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (HKD K) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%) | -33.3 | -17.9 | -41.7 | -19.6 | 60.0 |
ROA (%) | -14.0 | -8.0 | -18.6 | -7.3 | 27.0 |
ROIC (%) | — | — | — | -13.2 | 38.4 |
Current ratio (x) | — | — | — | 1.5 | 2.2 |
Debt to equity (%) | 19.8 | 23.7 | 36.2 | 44.1 | 23.7 |
Net debt to equity (%) | — | — | 24.1 | 36.3 | 5.4 |
Net debt to EBITDA (x) | — | — | -0.48 | -1.94 | 0.11 |
Interest coverage (x) | -26.6 | -12.8 | -23.2 | -7.2 | 33.4 |
Asset turnover (x) | 0.64 | 0.84 | 0.38 | 0.45 | 0.43 |
DSO, trade receivables (days) | — | — | — | 263 | 115 |
DPO, trade payables (days) | — | — | — | 121 | 92 |
Cash conversion cycle (days) | — | — | — | 142 | 23 |
Region revenue (HKD K)
| Region revenue (HKD K) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Hong Kong | 35,141 | 36,202 | 35,441 |
PRC (Mainland China) | 0 | 0 | 2,114 |
Total | 35,141 | 36,202 | 37,555 |
Region growth YoY (%)
| Region growth YoY (%) | FY2025 | FY2026 |
|---|---|---|
Hong Kong | 3.0 | -2.1 |
Share Price History
| Date | Price (HKD) | Source |
|---|---|---|
15 May 2026 | 0.243 (real-time quote) | etnet |
Early Jul 2026 | 0.106–0.113 | Lixinger / etnet |
22 Sep 2026 | 0.09 (-10% on day) | GrowthInvesting |
Performance metric | Value | Source / note |
3-year price change | About -28.6% | GrowthInvesting |
Annualised return since listing | About -45.9% per year | Lixinger (early Jul 2026) |
Board lot | 10,000 shares | Lixinger; 2021 announcement |
Liquidity | Very thin; HK$161k turnover on a sample day (0.5% turnover) | Lixinger |
Valuation Snapshot
| Multiple | Value | Calculation |
|---|---|---|
Market capitalisation | HK$27.2M | 301.86M shares × HK$0.09 |
Enterprise value | HK$29.9M | Market cap + HK$12.0M bond − HK$9.3M cash |
EV excluding listed securities | About -HK$21.5M | EV − HK$51.4M FVTPL assets |
P/E (trailing, reported) | 1.2x | 0.09 / 0.0772 |
P/E excluding fair-value and disposal gains | Not meaningful (core loss) | — |
EV/EBITDA | 1.2x | 29.9 / 24.1 |
EV/Sales | 0.80x | 29.9 / 37.6 |
P/B | 0.54x | 27.2 / 50.5 |
Lixinger quoted (early Jul 2026, price 0.106) | P/E 1.37x, P/B 0.63x; HK heavy-infrastructure sub-sector P/E 4.82x, P/B 0.27x | Lixinger |
Capital Markets
| Item | Detail |
|---|---|
Analyst consensus | No sell-side coverage; no price targets |
Dividend history | No dividends paid in FY2022–FY2026. Distributable reserves at company level are nil. |
Dividend policy | Adopted March 2019; discretionary, based on performance, cash, reserves and outlook |
Buybacks | None since listing. A repurchase mandate (up to 10%) was proposed at the 2026 AGM. |
Credit ratings | None (Moody's, S&P and Fitch do not rate the company) |
Share options outstanding | 19,842,480 (6.6% of issued shares): 10,698,480 at HK$0.315 (5-year term from 12 Jul 2021, now expired or expiring) and 9,144,000 at HK$0.163 (expire around 18 Mar 2027). Weighted average exercise price HK$0.245. |
Capital Instruments
| Instrument | Principal | Rate | Maturity | Status |
|---|---|---|---|---|
Unsecured bonds | HK$12.0M | 6% | 2 Dec 2022 | Overdue; repayable on demand. Undiscounted cash flow HK$12.72M within one year. |
Bank facilities | — | — | — | No general banking facilities |
Analyst Conclusions
Management guidance and consensus
Management provides no quantitative guidance. Qualitatively, it expects to:
-
pursue broader construction opportunities, especially in the public sector;
-
seek workforce certifications to win higher-value contracts;
-
develop the health technology and medical-device business under the dual-engine strategy.
There are no consensus forecasts. The near-term revenue floor is HK$32.8M of remaining performance obligations expected within one year (FY2026 AR note 8). The next scheduled catalyst is interim results for the six months to 30 September 2026, expected around late November 2026.
Bull case
-
Asset backing. Listed securities of HK$51.4M plus cash of HK$9.3M total HK$60.7M, more than twice the market capitalisation of about HK$27M. Even after the HK$15.7M bond and accrued interest, net liquid assets of about HK$45M exceed the market value.
-
Order book. Construction backlog of HK$394.2M across 13 contracts, with HK$32.8M due within one year, underpins about HK$35M of stable revenue. The HK$120bn-a-year government capital works programme supports tender opportunities.
-
Pivot upside with low fixed costs. The asset-light structure (no PPE, 23 staff, admin costs falling 8.8%) and HK$81M of tax losses mean that any scalable health-tech revenue could flow through at high incremental margins.
Bear case
-
Earnings are portfolio marks. The FY2026 profit is wholly attributable to HK$27.4M of fair-value gains. 30% of total assets sits in one Main Board micro-cap (亞洲策略) whose investee recorded a pre-tax loss of RMB8.4M on RMB276.5M revenue. A reversal could erase most of the equity gain.
-
Structural decline in the core business. Revenue has fallen about 95% from its FY2017 peak. Gross margin is 2.7% and customer concentration is 85%. The core business lost about HK$7.5M before investment gains in FY2026, and receivables carry a 64% loss allowance.
-
Credit, governance and dilution overhangs. The bond has been overdue since 2022. There is no internal audit, related-party asset sales, an auditor change over fees, a 2021 rights issue, and fresh issue and option mandates. A fragmented shareholder base with no controlling shareholder raises the risk of further dilutive capital raises to fund the "biotech" strategy.
Catalysts and monitorables (next 12 months)
| Monitorable | Why it matters | Timing |
|---|---|---|
| Interim results (H1 FY2027) | Mark-to-market on the portfolio; core construction margin; health-tech scale | Around late Nov 2026 |
| Bond resolution (repayment, extension or enforcement) | Removes or crystallises the principal credit overhang | Any time |
| Customer A contract renewals and new tenders | 85% revenue dependency | Ongoing |
| Health-tech disclosures (products, approvals, partners, capital injection into the Shenzhen subsidiary) | Tests credibility of the rebrand | Ongoing |
| Portfolio actions (disposals of 亞洲策略 and Tam Kam stakes) | Crystallising gains would validate NAV | Ongoing |
| Equity issuance under the 20% general mandate or option grants | Dilution risk | Post-AGM (10 Sep 2026) |
| HK$3.0M flooding litigation | Contingent liability | Ongoing |
| Option expiry (9.144M at HK$0.163) | Minor overhang removal | Around Mar 2027 |
| Board and committee reconstitution (nomination chair after Liao) | Governance quality | Near term |
Analyst verdict
Ju Fu Tang Biotech is best understood as a listed shell-like holding company with three loosely related assets: a shrinking construction subcontractor, a volatile small-cap equity book, and an unproven health-technology option. The FY2026 headline swing from a HK$5.9M loss to a HK$23.3M profit is real in accounting terms but not operational. Fair-value gains of HK$27.4M exceeded total net profit, while the construction division made HK$437k of segment profit on HK$35.4M of revenue, and the new medical-device unit lost HK$19k.
The balance sheet is genuinely stronger. Equity has nearly doubled to HK$50.5M, net debt is HK$2.7M and the current ratio is 2.2x. Yet the composition of that equity is fragile. More than half of all assets are three Hong Kong micro-cap positions, one of which lost three-quarters of its value in the same year another tripled.
The market is pricing these risks aggressively. At HK$0.09, the stock trades at about 0.54x book and well below the value of its listed securities alone. That discount is rational given the long-overdue HK$12M bond, extreme customer concentration, poor receivable recoverability, related-party dealings, no internal audit and a history of dilutive capital raising.
The rebrand to a "biotech" identity is, at present, a statement of intent rather than an operating reality. There is no R&D, no IP, no disclosed product pipeline, and the Shenzhen subsidiary's registered capital is unpaid. For deep-value or special-situation investors, the asset discount offers asymmetric upside if management crystallises portfolio gains, retires the bond and demonstrates credible health-tech traction. For most institutional mandates, liquidity, governance and earnings-quality issues make the shares uninvestable.
Overall assessment: speculative, NAV-driven situation. Monitor the November 2026 interims, bond resolution and any capital-raising before taking any view beyond a watch-list position.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Age | Appointed | Background and education | FY2026 total emoluments (HKD K) |
|---|---|---|---|---|---|
Mr. Chen Jian (陳健) | Executive director; compliance officer; authorised representative; signs the Chairman's Statement | 62 | — | 30+ years of corporate management experience in Hong Kong and the PRC. Responsible for business development and general administration. No other listed directorships in the past three years. | 120 (fees only) |
Ms. Yu Xiao (余曉) | Executive director; remuneration committee member | 45 | 16 Nov 2017 | 10+ years in civil engineering and real estate construction. Formerly architect and civil engineering department engineer at 湖南和慶源建設工程有限公司. BEng in civil engineering, Hunan University (June 2000). | 120 |
Mr. Wong Chi Kan (黃智瑾) | INED; chair of audit and remuneration committees | 40 | 12 Apr 2016 | Finance director at a private company since June 2017. Previously assistant finance director at a financial PR firm and accounting manager at a GEM-listed packaging company, plus several accounting firms. BCom (2009) and Master of Professional Accounting (2010), University of New South Wales. FCPA (CPA Australia, since March 2014). HKICPA practising accountant. | 120 |
Ms. Lao In Iam (劉燕欽) | INED; audit and nomination committee member | 53 | 18 Aug 2020 | 20+ years in construction, including overall management and supervision of large projects in Macau. | 96 |
Ms. | INED; audit, remuneration and nomination committee member | 55 | 17 Aug 2026 | 20+ years in corporate governance, internal control review, pre-listing compliance, risk oversight and fraud prevention. MBA, Chinese University of Hong Kong. BA (Hons) Accounting and Finance, University of Glamorgan. FCPA (HKICPA), FCCA, Certified Internal Auditor. Fee HK$120k per year, three-year appointment. | n/a (appointed after FY2026) |
Mr. Liao Honghao (廖洪浩) — resigned | Former INED; chaired nomination committee | 66 | 2 Mar 2018 to 17 Aug 2026 | Marketing general manager at a PRC publishing company. 30+ years in strategic planning and promotion. Meizhou Radio and TV University. | 102 |
Directors' Remuneration
| Feature | Detail |
|---|---|
Board size / independence | 5 directors: 2 executive and 3 INEDs (60% independent) |
Chair / CEO separation | No formal chairman or CEO is named. The FY2026 AR describes Mr. Liao Honghao as "executive director and chairman" in the nomination committee section, which is inconsistent with his INED status. This is likely a drafting error and is a governance-quality flag. |
Audit committee | Wong Chi Kan (chair), Lao In Iam, Liao Honghao (replaced by Ms. Wong Mei Yin from 17 Aug 2026). Met 3 times in FY2026 with full attendance. |
Remuneration committee | Wong Chi Kan (chair), Liao Honghao (replaced by Ms. Wong Mei Yin), Yu Xiao. Met 3 times. |
Nomination committee | Liao Honghao (chair until 17 Aug 2026), Wong Chi Kan, Lao In Iam. The current chair after Mr. Met 3 times. |
Board meetings | 6 in FY2026, with 100% attendance by all directors. |
Internal audit | No internal audit function. An external internal-control consultant performs an annual review. The framework references COSO 2013. |
Gender diversity | 3 of 5 directors are women after August 2026 (Yu Xiao, Lao In Iam, Wong Mei Yin). |
Retirement by rotation (2026 AGM) | Chen Jian and Wong Chi Kan, plus Ms. Wong Mei Yin, who was appointed to fill a casual vacancy. |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
Around Sep–Oct 2023 | Ms. Lau Wing Yu (劉詠愉) ceases as executive director; Mr. Chen Jian joins as executive director and compliance officer (3 Oct 2023) | Coincides with the rebranding to WMHW |
25 Apr 2024 | Auditor change from 開元信德 to Infinity CPA (致寶信勤) | Fee disagreement for FY2024 audit |
17 Aug 2026 | Mr. Liao Honghao resigns as INED; Ms. Wong Mei Yin appointed | Adds governance and internal-audit expertise to the board |
Major Shareholders
| Holder | Interest | % of issued shares | Source |
|---|---|---|---|
Ms. Yu Xiao (executive director) | 780,000 (shown as personal interest and underlying shares) | 0.26% | FY2026 AR |
Mr. Liao Honghao (former INED) | 780,000 | 0.26% | FY2026 AR |
Ms. Lao In Iam (INED) | 780,000 | 0.26% | FY2026 AR |
Substantial shareholders (5% or more) | None disclosed in the SFO s.336 register | — | FY2026 AR |
Institutional holders (top 10) | Not publicly disclosed. No institutional holders identified. | — | — |
Total insider ownership | About 0.78% (2,340,000 shares or underlying shares) at 31 Mar 2026 | 0.78% | FY2026 AR |
Competitive Landscape
Key Competitors
| Company (ticker) | Segment overlap | Latest revenue | Positioning vs. Ju Fu Tang |
|---|---|---|---|
Kwong Luen Engineering Holdings (1413) | HK civil engineering | HK$618.2M, FY to Mar 2024; gross margin 5.6%; profit before tax HK$21.2M | About 16x larger; profitable at operating level |
WLS Holdings / 滙隆控股 (GEM) | HK scaffolding and fitting-out (also an investee) | About HK$76M revenue and HK$39.5M profit before tax for 6 months to 31 Oct 2025 (as cited in the FY2026 AR) | Peer and portfolio holding |
Sang Hing Holdings (International) (1472) | HK civil engineering (site formation, roads and drainage) | — | Larger, comparable work type |
Kingland Group Holdings (listed as a peer by TipRanks) | HK construction subcontracting | — | Similar micro-cap peer |
Build King Holdings (240) | HK civil engineering main contractor | — | Tier-1 contractor; potential customer and competitor |
Asia Allied Infrastructure / Chun Wo (711) | HK civil engineering | — | Tier-1 contractor |
Chinney Alliance / Chinney Kin Wing (385) | HK foundations and civil works | — | Larger specialist |
Kwan On Holdings (1559) | HK civil engineering subcontracting | — | Comparable subcontractor |
Unlisted HK subcontractors (various) | Roads, drainage, site formation, fit-out | — | Price competition in tenders |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | Ju Fu Tang (FY2026) | Kwong Luen (FY2024) | WLS Holdings (6 months to Oct 2025) | Sang Hing (FY2023) |
|---|---|---|---|---|
Revenue (HKD Mn) | 37.6 | 618.2 | about 76 (half-year) | — |
Revenue growth | +3.7% | — | — | Civil revenue about -24% (FY2023) |
Gross margin | 2.7% | 5.6% | — | Declined (FY2023) |
Pre-tax result (HKD Mn) | 23.3 (investment-driven) | 21.2 | about 39.5 (half-year) | about -9 (net loss) |
R&D intensity | 0% | Not disclosed (assumed nil) | — | — |
“—” = not publicly disclosed.



